Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 3/5 criteria met. Data as of 11/11/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: -0.56%
Price change 2019 → 2020: 19.15%
Price change 2020 → 2021: 18.79%
Price change 2021 → 2022: -26.70%
Price change 2022 → 2023: 7.26%
Price change 2023 → 2024: 143.60%
Price change 2024 → 2025: 24.14%
Price change 2025 → 2026: 23.89%
Price change 2026 (year to date): 26.22%
Financial growth
Revenue CAGR (8 years): 7.61%
Earnings CAGR (8 years): 9.99%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.21
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 25.55
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 1.07% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="UCB.BR" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| UCB S.A. | 25.7 | 0.21 | +6.0 % | 🔒 |
| Bayer AG | 11.7 | 1.44 | +1.8 % | – |
| Boston Scientific Corporation | 14.3 | 0.51 | +6.5 % | – |
| Becton, Dickinson and Company | 16.8 | 0.76 | +6.5 % | – |
| Cencora, Inc. | 20.9 | 6.19 | +9.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by UCB S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 5.9 bn | 807 m | 13.7 % | n/a |
| 2021 | 6.4 bn | 1.2 bn | 18.3 % | +8.0 % |
| 2022 | 6.1 bn | 461 m | 7.6 % | -4.5 % |
| 2023 | 5.8 bn | 378 m | 6.5 % | -4.8 % |
| 2024 | 6.8 bn | 1.2 bn | 17.3 % | +17.1 % |
| 2025 | 8.5 bn | 1.7 bn | 20.1 % | +25.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by UCB S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 1.4 bn | 1.1 bn | 923 m | 1.8 bn | 2.5 bn |
| Total Debt | 2.1 bn | 2.9 bn | 3.0 bn | 3.0 bn | 2.2 bn |
| Net Debt | 860 m | 2.0 bn | 2.2 bn | 1.5 bn | -6.0 m |
| Equity | 8.4 bn | 9.1 bn | 9.0 bn | 10.0 bn | 10.9 bn |
| Total assets | 14.2 bn | 15.9 bn | 15.5 bn | 17.3 bn | 18.2 bn |
| Operating cash flow | 1.5 bn | 1.0 bn | 761 m | 1.2 bn | 2.2 bn |
| Investments (capex) | 493 m | 371 m | 238 m | 234 m | 449 m |
| Free cash-flow | 997 m | 674 m | 445 m | 920 m | 1.9 bn |
| Share buybacks | 60.0 m | 42.0 m | 40.0 m | 162 m | 121 m |
| Dividends paid | 240 m | 247 m | 252 m | 259 m | 264 m |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
UCB S.A. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| UCB S.A. | 62.3 bn | 25.7 | 20.1 % |
| Amgen Inc. AMGN | 252 bn | 20.8 | 21.0 % |
| AbbVie Inc. ABBV | 521 bn | 28.9 | 6.9 % |
| Regeneron Pharmaceuticals, Inc. REGN | 98.8 bn | 20.9 | 31.4 % |
| Eli Lilly and Company LLY | 1,358 bn | 45.8 | 31.7 % |
| Incyte Corporation INCY | 24.7 bn | 16.3 | 25.0 % |
| Celltrion, Inc. 068270.KS | 36.5 bn | 32.7 | 24.8 % |
| Novartis AG NOVN.SW | 302 bn | 19.5 | 25.6 % |
| Vertex Pharmaceuticals Incorporated VRTX | 137 bn | 28.3 | 32.7 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering UCB S.A. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 8.9 bn | 2.4 bn | 12.70 (10.74 / 15.33) | 23.3 | 16 |
| 2027 | 9.9 bn | 2.8 bn | 14.71 (13.37 / 17.47) | 20.2 | 16 |
| 2028 | 11.0 bn | 3.3 bn | 17.48 (14.79 / 21.35) | 17.0 | 12 |
Amounts in EUR, the reporting currency.
Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
UCB S.A.: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 04/05/2026 | 1.45 EUR | n/a |
| 25/04/2025 | 1.39 EUR | 29/04/2025 |
| 26/04/2024 | 1.36 EUR | 30/04/2024 |
| 28/04/2023 | 1.33 EUR | 03/05/2023 |
| 29/04/2022 | 1.30 EUR | 03/05/2022 |
| 30/04/2021 | 1.27 EUR | 04/05/2021 |
| 04/05/2020 | 1.24 EUR | 06/05/2020 |
| 26/04/2019 | 1.21 EUR | 30/04/2019 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 30/07/2026 | 6.77 | 5.03 | +34.6 % |
| 26/02/2026 | 6.44 | 4.95 | +30.1 % |
| 31/07/2025 | 3.59 | 3.36 | +6.8 % |
| 27/02/2025 | 2.85 | 2.58 | +10.5 % |
| 25/07/2024 | 2.06 | 1.74 | +18.4 % |
| 25/04/2024 | 1.58 | 1.36 | +16.2 % |
Stock splits
| Date | Operation |
|---|---|
| 04/01/1999 | split: 100 shares for 1 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in UCB S.A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about UCB S.A.
What is the UCB S.A. share price?
Latest recorded price: 296.50 EUR on 13/11/2026, for a market cap of 62.3 bn USD.
What is the revenue of UCB S.A.?
8.5 bn USD for fiscal year 2025, with net income of 1.7 bn USD (net margin 20.1 %).
Does UCB S.A. pay a dividend?
Yes. Latest dividend: 1.45 EUR per share, ex-dividend on 04/05/2026. Over 12 months: 1.45 EUR. Yield on the latest known price: 0.6 %.
When does UCB S.A. report its next earnings?
The next release is expected on 25/02/2027. EPS expected by analysts: 7.09.
What do analysts say about UCB S.A.?
Out of 2 analysts: 2 buy or strong buy, 0 hold, 0 sell or strong sell.
What is the P/E ratio of UCB S.A.?
Trailing 12-month P/E of 25.7.
Is UCB S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN BE0003739530) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does UCB S.A. have?
9,052 full-time employees according to the latest published profile.
Who runs UCB S.A.?
Jean-Christophe Tellier is the company's chief executive.